Clinical Trials Logo

Sepsis clinical trials

View clinical trials related to Sepsis.

Filter by:

NCT ID: NCT04285021 Completed - Sepsis Clinical Trials

Prediction of Disease Severity in Young Children Presenting With Acute Febrile Illness in Resource-limited Settings

SPOT-SEPSIS
Start date: March 5, 2020
Phase:
Study type: Observational

Note that this is a study that is co-sponsored by Medecins Sans Frontieres, Spain, and the University of Oxford. The primary objective is to develop a risk prediction algorithm, combining measurements of host biomarkers and clinical features at the point-of-triage, for children with an acute febrile illness in resource-limited settings. The secondary objectives are to determine which host biomarkers, feasible for measurement at the point-of-care, are predictive of disease severity. Additionally to determine the optimal combination of clinical features (including demographics, anthropometric data, historical variables, vital signs, clinical signs and clinical symptoms), feasible for assessment by limited-skill health workers, that is predictive of disease severity. The tertiary objectives are to explore the impact of different methods of outcome classification on development of the risk prediction algorithm, and to explore the performance of the algorithm to predict disease severity in key presenting clinical syndromes and aetiologies.

NCT ID: NCT04261621 Completed - Sepsis Clinical Trials

Early Identification of SEPsis SIGNs in Emergency Department

SepSIGN
Start date: July 6, 2020
Phase:
Study type: Observational

Objective of SepSIGN project is to validate biomarkers able to predict the clinical worsening of patients freshly admitted at Emergency Department. Targeted population is adult patients, freshly admitted at ED, with a suspected or confirmed infection.

NCT ID: NCT04255979 Completed - Sepsis Clinical Trials

A Study of HY209 in Healthy Male Volunteers for Sepsis

Start date: December 5, 2019
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, placebo-controlled single dosing, dose escalation phase I clinical trial to investigate the safety/tolerability and pharmacokinetics of HY209 after intravenous administration in healthy male volunteers

NCT ID: NCT04227652 Completed - Sepsis Clinical Trials

Control of Fever in Septic Patients

COVERSEP
Start date: September 3, 2013
Phase: N/A
Study type: Interventional

The benefits of fever treatment in critically ill patients remains unclear. The aim of the prospective, randomized clinical trial was to verify the hypothesis that the administration of ibuprofen in order to decrease the fever in septic patients without limited cardiorespiratory reserve leads to decreasing their prognosis.

NCT ID: NCT04226430 Completed - Sepsis Clinical Trials

Effect of Cytosorb on Blood Levels of Inflammatory Biomarkers of Sepsis.

Start date: June 1, 2016
Phase:
Study type: Observational [Patient Registry]

Background: There is still an evident need for useful biomarkers and effective therapeutic approaches regarding the challenging management of sepsis. The aim of the study is to evaluate the effect of each Cytosorb hemoadsorption therapy course on blood levels of inflammatory biomarkers of sepsis including endocan, copeptin, interleukin-6, procalcitonin, C-reactive protein.

NCT ID: NCT04217629 Completed - Sepsis Clinical Trials

Single-dose/Multiple-doses Incremental Intravenous Injection of SY-005 (Recombinant Human Annexin A5)in Healthy Subjects

Start date: April 26, 2019
Phase: Phase 1
Study type: Interventional

This is a single-dose/multiple-doses incremental, randomized, double-blind, parallel, placebo-controlled study on safety, tolerance and pharmacokinetics healthy subjects.

NCT ID: NCT04216459 Completed - Sepsis Clinical Trials

Effect of Anti-inflammatory and Anti-microbial Co-supplementations in Traumatic ICU Patients at High Risk of Sepsis

DrNoha-ICU
Start date: February 18, 2020
Phase: N/A
Study type: Interventional

The occurrence of sepsis in trauma patients is a very serious complication. Identifying trauma patients at high risk of sepsis was not revealed in the latest surviving sepsis campaign in 2016. Several biomarkers have been proposed for early prediction of sepsis in trauma patients as leukocyte anti sedimentation rate (LAR) and the proinflammatory cytokine monocyte chemo attractant protein-1 (MCP-1). Sepsis prophylaxis before occurrence of multi-organ failure still represents a major challenge. Vitamin D and probiotics have antimicrobial, anti-inflammatory and gut microbiota immune modulatory properties.Little is known about the effect of vitamin D and probiotics co-supplementation on the inflammatory response in trauma patients at high risk of sepsis. Another promising strategy is the use of vitamin C in addition to thiamine. Trauma is associated with increased oxidative stress and vitamin C deficiency. High dose vitamin C is required to restore oxidant-antioxidant balance. Vitamin C and thiamine have shown promising results in treatment of sepsis. Vitamin C possesses anti-inflammatory, endothelial protective and anti-microbial effects. Thiamine is the precursor of thiamine pyrophosphate (TPP), a key enzyme in Krebs cycle.

NCT ID: NCT04214743 Completed - Sepsis Clinical Trials

Ocular Microvascular Changes in Patients With Sepsis

Start date: January 2, 2018
Phase:
Study type: Observational

This study evaluates differences in the ocular microcirculation between septic patients and healthy subjects and the course of ocular microvasculature in survivors and non-survivors over a 24 hours period of time in septic patients

NCT ID: NCT04203784 Completed - Sepsis Clinical Trials

Meropenem and Piperacillin Plasma Concentrations During CRRT

ABC2
Start date: November 1, 2012
Phase:
Study type: Observational

This observational study reports meropenem and piperacillin plasma concentrations in patients treated with either antibiotic and simultaneous continuous renal replacement therapy (CRRT).

NCT ID: NCT04197115 Completed - Sepsis Clinical Trials

Vitamin C, Thiamine, Cyanocobalamine, Pyridoxine and Hydrocortisone in Sepsis

Start date: September 1, 2019
Phase: Phase 3
Study type: Interventional

Prospective, experimental, longitudinal cohort study in septic patients treated at ER and ICU at General Hospital Zone 11 IMSS Piedras Negras Coahuila. Interventions, will be implementd in 2 consecutive periods of 6 months Phase 1: 6 months period, septic patients treated only with standard treatment. Phase 2: 6 months period, septic patients treated with Vitamin C, Thiamine, Cyanocobalamine, Pyridoxine and Hydrocortisone + standard treatment.